1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Tot Biopharm Co. Ltd.

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2009

Location

Suzhou Jiangsu China

Primary Industry

Pharmaceuticals

About

Established in 2009 and based in Suzhou, China, Tot Biopharm Co. Ltd. operates as a new drug developer that mainly provides new antitumor drugs. It has sub-branches offices in Beijing and Shanghai, and has a production base in Suzhou. In August 2018, the company raised USD 102 million in series B funding led by new investor China Universal Asset Management. In November 2019, Tot Biopharm Co. Ltd. was listed on the Hong Kong Stock Exchange. The company mainly provides new antitumor drugs and CDMO (Contract Development and Manufacturing Organization) service. Products include bevacizumab injection, temozolomide capsules, and megestrol acetate oral suspension. Services include ADC (antibody-drug conjugate) integrated platform, protein/antibody platform, and GMP (Good Manufacturing Practice) production. The ADC integrated platform includes coupling process development and optimization, formulation prescription and freeze-drying process, analytical services, etc. The company generates revenue by providing new antitumor drugs and CDMO service.
Current Investors
Chengwei Capital, Vivo Capital, Formosa Laboratories, Inc.

Request a demo to show more

Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Healthcare IT, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.totbiopharm.cn
Verticals
HealthTech, Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only

Financials

Fiscal Year Ended
Revenue (USD)
% Revenue Growth (YoY)
Operating Income (USD)
Operating Margin
EBITDA (USD)
% EBITDA Margin
NET Income (USD)
% Net Margin
31 Dec 2018
39,219,000
-
(237,177,000)
(604.8%)
(221,521,000)
(564.8%)
(268,263,000)
(684%)
31 Dec 2019
31 Dec 2020
31 Dec 2021

Unlock the recent years of financials and more for Tot Biopharm Co. Ltd..

Request a demo to see more.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.